Efficacy and safety of baricitinib versus azathioprine, both combined with topical corticosteroids, in patients with moderate-to-severe atopic dermatitis: a single-centre …
1. 系统已在2026-03-23 11:52:27对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
M Malekan, G Rahmatpour Rokni…
British Journal of …, 2025
academic.oup.com
Background Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can be difficult to manage in moderate-to-severe cases. Baricitinib (a Janus kinase 1/2 inhibitor) and azathioprine (a traditional immunosuppressant) are both used in the systemic treatment of AD. Objectives To compare the efficacy and safety of baricitinib vs. azathioprine, both combined with topical corticosteroids (TCS), in adults with moderate-to-severe AD. Methods In this single-centre open-label randomized head-to-head trial (NCT05969730), 40 adults …
